Layoffs
Merck announced that it will be laying off 143 people from the Cambridge, Massachusetts-based Acceleron.
Orchard Therapeutics announced today that it intends to focus its hematopoietic stem cell (HSC) gene therapy platform exclusively on severe neurometabolic diseases and early research programs.
Orion Corporation announced its plans to shift focus to new proprietary drugs in oncology and pain, expecting to cut 37 jobs.
Neurana Pharmaceuticals is facing dire financial straits following the failure of its Phase III treatment for muscle spasm relief associated with an acute, painful musculoskeletal condition.
Athenex announced that it is scaling its operations by more than 50%, while Zosano Pharma announced that it is reducing its workforce by around 31%.
The Orphazyme board of directors decided to cut 50% of its current global staff count after carefully considering its financial state.
Gilead Sciences is letting go of 114 employees following an underwhelming response to the results reaped so far from its $21 billion acquisition of Immunomedics in 2020.
Shares of Adaptive are climbing this morning after the company announced a reorganization of priorities to spur future growth, including a workforce reduction of approximately 12%.
After months of speculation about looming layoffs, Biogen is handing out pink slips in order to save about $500 million.
Gemini will undertake a corporate restructuring that will see a drastic 80% of its workforce laid off.
PRESS RELEASES
